Neoadjuvant Therapy for HER2-Positive Breast Cancer

Program Goals

Rationale for Neoadjuvant Therapy in Early BC

NOAH Trial: Study Design

NOAH: Secondary End Point: pCR

Neoadjuvant Trials With Trastuzumab: pCR

FDA Meta-analysis

Neoadjuvant Trials of Trastuzumab and/or Lapatinib

Neo ALTTO

NeoALTTO: Total pCR and by HR Status

NeoALTTO Efficacy: Median Follow-up More Than 3 Years

Conclusions From Adjuvant Setting: ALTTO Findings

Pertuzumab Binds to Extracellular Domain of HER2: Blocks Ligand-induced Dimerization of HER2 and HER3

NeoSphere: Study Design

NeoSphere: Efficacy

NeoSphere: 10 Most Common AEs With Dual Anti-HER2 Blockade (Any Grade)

NeoSphere Most Common AEs With Dual Anti-HER2 Blockade (Grade 3 or Higher)

TRYPHAENA: Neoadjuvant Trastuzumab and Pertuzumab in HER2+ Early BC: Study Design (Phase 2)

TRYPHAENA: End Points

TRYPHAENA: Cardiac Safety

TRYPHAENA Notable Grade 3/4 AEs

TRYPHAENA: pCR

Neoadjuvant Trials: Trastuzumab + Pertuzumab

FDA Approval: Pertuzumab in Neoadjuvant Treatment of HER2+ BC

Limitations

BERENICE Study Design

Adjuvant Pertuzumab? NCCN Recommendations*

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)